Cisplatin
Posted on: March 17, 2024 *Updated on: May 27, 2024Cisplatin is a cornerstone in the treatment of various cancers, including mesothelioma, a type of cancer that affects the lining of the lungs, usually linked to asbestos exposure. As a platinum-based chemotherapy drug, cisplatin works by damaging the DNA in cancer cells, preventing them from dividing and growing. When used in combination with Alimta (pemetrexed), it has been shown to improve survival rates in patients with pleural mesothelioma, which is the most common type of mesothelioma, affecting the lining of the lungs.
The Food and Drug Administration (FDA) has approved the combination of cisplatin and Alimta for the treatment of patients with malignant pleural mesothelioma who are not candidates for surgery. This approval is based on clinical studies showing that this combination can improve survival outcomes. Specifically, studies have demonstrated that patients receiving cisplatin in combination with Alimta have median survival times ranging from 12 to 15 months. This is considered a significant improvement, given the aggressive nature of mesothelioma and its poor prognosis.
The treatment regimen usually involves cycles of cisplatin and Alimta administration, followed by periods of rest to allow the patient’s body to recover from the side effects, which can include nausea, vomiting, kidney toxicity, and nerve damage among others. The specific dosing schedule and duration of treatment may vary based on the patient’s overall health, the stage of the disease, and how the patient responds to therapy.
The combination of cisplatin and Alimta is a key therapeutic option for pleural mesothelioma, offering hope to patients with limited treatment options. However, the management of side effects and careful monitoring of the patient’s condition are essential components of the treatment process to ensure the best possible outcomes.